Works matching DE "LENALIDOMIDE"

Results: 301
    1
    2
    3
    4
    5
    6

    Exposure‐response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma.

    Published in:
    CPT: Pharmacometrics & Systems Pharmacology, 2022, v. 11, n. 6, p. 766, doi. 10.1002/psp4.12789
    By:
    • Rachedi, Fatiha;
    • Koiwai, Kimiko;
    • Gaudel‐Dedieu, Nadia;
    • Sebastien, Bernard;
    • Thai, Hoai‐Thu;
    • Brillac, Claire;
    • Fau, Jean Baptiste;
    • Nguyen, Laurent;
    • van de Velde, Helgi;
    • Veyrat‐Follet, Christine;
    • Semiond, Dorothée
    Publication type:
    Article
    7
    8
    9
    10
    11
    12

    Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis.

    Published in:
    Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.826342
    By:
    • Mian, Hira;
    • Eisfeld, Christine;
    • Venner, Christopher P.;
    • Masih-Khan, Esther;
    • Kardjadj, Moustafa;
    • Jimenez-Zepeda, Victor H.;
    • Khandanpour, Cyrus;
    • Lenz, Georg;
    • McCurdy, Arleigh;
    • Sebag, Michael;
    • Song, Kevin;
    • LeBlanc, Richard;
    • White, Darrell;
    • Stakiw, Julie;
    • Reiman, Anthony;
    • Louzada, Martha;
    • Aslam, Muhammad;
    • Kotb, Rami;
    • Gul, Engin;
    • Reece, Donna
    Publication type:
    Article
    13

    Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide.

    Published in:
    Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-49529-x
    By:
    • Serrano, Guillermo;
    • Berastegui, Nerea;
    • Díaz-Mazkiaran, Aintzane;
    • García-Olloqui, Paula;
    • Rodriguez-Res, Carmen;
    • Huerga-Dominguez, Sofia;
    • Ainciburu, Marina;
    • Vilas-Zornoza, Amaia;
    • Martin-Uriz, Patxi San;
    • Aguirre-Ruiz, Paula;
    • Ullate-Agote, Asier;
    • Ariceta, Beñat;
    • Lamo-Espinosa, Jose-Maria;
    • Acha, Pamela;
    • Calvete, Oriol;
    • Jimenez, Tamara;
    • Molero, Antonieta;
    • Montoro, Maria Julia;
    • Díez-Campelo, Maria;
    • Valcarcel, David
    Publication type:
    Article
    14

    Correction: Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients.

    Published in:
    2024
    By:
    • Alcantara, Marion;
    • Chevrier, Marion;
    • Jardin, Fabrice;
    • Schmitt, Anna;
    • Houillier, Caroline;
    • Oberic, Lucie;
    • Chinot, Olivier;
    • Morschhauser, Franck;
    • Peyrade, Frédéric;
    • Houot, Roch;
    • Hoang-Xuan, Khê;
    • Ghesquieres, Hervé;
    • Soussain, Carole
    Publication type:
    Correction Notice
    15
    16

    Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.

    Published in:
    British Journal of Haematology, 2022, v. 199, n. 3, p. 355, doi. 10.1111/bjh.18432
    By:
    • Sborov, Douglas W.;
    • Baljevic, Muhamed;
    • Reeves, Brandi;
    • Laubach, Jacob;
    • Efebera, Yvonne A.;
    • Rodriguez, Cesar;
    • Costa, Luciano J.;
    • Chari, Ajai;
    • Silbermann, Rebecca;
    • Holstein, Sarah A.;
    • Anderson, Larry D.;
    • Kaufman, Jonathan L.;
    • Shah, Nina;
    • Pei, Huiling;
    • Patel, Sharmila;
    • Cortoos, Annelore;
    • Bartlett, J. Blake;
    • Vermeulen, Jessica;
    • Lin, Thomas S.;
    • Voorhees, Peter M.
    Publication type:
    Article
    17
    18
    19
    20

    A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher‐Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations.

    Published in:
    British Journal of Haematology, 2022, v. 198, n. 3, p. 535, doi. 10.1111/bjh.18193
    By:
    • Adès, Lionel;
    • Duployez, Nicolas;
    • Guerci‐Bresler, Agnes;
    • Laribi, Kamel;
    • Peterlin, Pierre;
    • Vey, Norbert;
    • Thepot, Sylvain;
    • Wickenhauser, Stefan;
    • Zerazhi, Hacene;
    • Stamatoullas, Aspassia;
    • Wattel, Eric;
    • Recher, Christian;
    • Toma, Andrea;
    • Dimicoli‐Salazar, Sophie;
    • Braun, Thorsten;
    • Beyne‐Rauzy, Odile;
    • Marolleau, Jean‐Pierre;
    • Cheze, Stéphane;
    • Park, Sophie;
    • Cluzeau, Thomas
    Publication type:
    Article
    21
    22

    Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.

    Published in:
    British Journal of Haematology, 2022, v. 196, n. 1, p. 105, doi. 10.1111/bjh.17772
    By:
    • Piedra, Katrina;
    • Peterson, Tim;
    • Tan, Carlyn;
    • Orozco, Jennifer;
    • Hultcrantz, Malin;
    • Hassoun, Hani;
    • Mailankody, Sham;
    • Lesokhin, Alexander;
    • Shah, Urvi;
    • Lu, Sydney;
    • Patel, Dhwani;
    • Derkach, Andriy;
    • Wilkins, Cy R.;
    • Korde, Neha
    Publication type:
    Article
    23

    A nationwide survey on central nervous system multiple myeloma in Japan: analysis of prognostic and treatment factors that impact survival.

    Published in:
    British Journal of Haematology, 2021, v. 195, n. 2, p. 217, doi. 10.1111/bjh.17717
    By:
    • Yamashita, Takeshi;
    • Takamatsu, Hiroyuki;
    • Kawamura, Koji;
    • Sunami, Kazutaka;
    • Hagiwara, Shotaro;
    • Itagaki, Mitsuhiro;
    • Takahashi, Tsutomu;
    • Kondo, Tadakazu;
    • Ikeda, Takashi;
    • Watakabe‐Inamoto, Kyoko;
    • Handa, Hiroshi;
    • Imaizumi, Yoshitaka;
    • Kuroda, Junya;
    • Murakami, Jun;
    • Nakamura, Yuichi;
    • Nakazawa, Hideyuki;
    • Ozaki, Shuji;
    • Okura, Miyuki;
    • Takeuchi, Masami;
    • Nagai, Hirokazu
    Publication type:
    Article
    24
    25

    Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from a large cohort of patients with long follow‐up.

    Published in:
    British Journal of Haematology, 2021, v. 195, n. 2, p. 230, doi. 10.1111/bjh.17685
    By:
    • Basset, Marco;
    • Kimmich, Christoph R.;
    • Schreck, Nicholas;
    • Krzykalla, Julia;
    • Dittrich, Tobias;
    • Veelken, Kaya;
    • Goldschmidt, Hartmut;
    • Seckinger, Anja;
    • Hose, Dirk;
    • Jauch, Anna;
    • Müller‐Tidow, Carsten;
    • Benner, Axel;
    • Hegenbart, Ute;
    • Schönland, Stefan O.
    Publication type:
    Article
    26

    Health‐related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial.

    Published in:
    British Journal of Haematology, 2021, v. 194, n. 1, p. 132, doi. 10.1111/bjh.17435
    By:
    • Plesner, Torben;
    • Dimopoulos, Meletios A.;
    • Oriol, Albert;
    • San‐Miguel, Jesus;
    • Bahlis, Nizar J.;
    • Rabin, Neil;
    • Suzuki, Kenshi;
    • Yoon, Sung‐Soo;
    • Ben‐Yehuda, Dina;
    • Cook, Gordon;
    • Goldschmidt, Hartmut;
    • Grosicki, Sebastian;
    • Qin, Xiang;
    • Fastenau, John;
    • Garvin, Wendy;
    • Carson, Robin;
    • Renaud, Thomas;
    • Gries, Katharine S.
    Publication type:
    Article
    27

    Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide‐based maintenance therapy.

    Published in:
    British Journal of Haematology, 2021, v. 193, n. 3, p. e23, doi. 10.1111/bjh.17393
    By:
    • Kunacheewa, Chutima;
    • Feng, Lei;
    • Manasanch, Elisabet E.;
    • Bashir, Qaiser;
    • Patel, Krina K.;
    • Mehta, Rohtesh;
    • Kaufman, Gregory P.;
    • Srour, Samer;
    • Saini, Neeraj;
    • Iyer, Swaminathan P.;
    • Thomas, Sheeba K.;
    • Weber, Donna M.;
    • Orlowski, Robert Z.;
    • Qazilbash, Muzaffar H.;
    • Lee, Hans C.
    Publication type:
    Article
    28

    Real‐world outcomes with bortezomib‐containing regimens and lenalidomide plus dexamethasone for the treatment of transplant‐ineligible multiple myeloma: a multi‐institutional report from the Canadian Myeloma Research Group database

    Published in:
    British Journal of Haematology, 2021, v. 193, n. 3, p. 532, doi. 10.1111/bjh.17350
    By:
    • Jimenez‐Zepeda, Victor H.;
    • Venner, Christopher;
    • McCurdy, Arleigh;
    • Masih‐Khan, Esther;
    • Atenafu, Eshetu G.;
    • Sebag, Michael;
    • Stakiw, Julie;
    • Song, Kevin;
    • LeBlanc, Richard;
    • Reiman, Tony;
    • Louzada, Martha;
    • Kotb, Rami;
    • Gul, Engin;
    • Reece, Donna
    Publication type:
    Article
    29
    30

    Daratumumab, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Meta‐Analysis.

    Published in:
    Hematological Oncology, 2025, v. 43, n. 3, p. 1, doi. 10.1002/hon.70061
    By:
    • Gordan, Lucio N.;
    • Medhekar, Rohan;
    • Fu, Alex Z.;
    • Shokoohi, Mostafa;
    • Oliva Ramirez, Abril;
    • Bonar, Nicolle;
    • Nguyen, Bao‐Ngoc;
    • Spence, Michaela;
    • McTavish, Rebecca;
    • Disher, Tim;
    • Gautam, Santosh;
    • Gupta‐Werner, Niodita;
    • Kaila, Shuchita;
    • Patel, Anjan J.
    Publication type:
    Article
    31
    32

    A real‐life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis.

    Published in:
    Hematological Oncology, 2024, v. 42, n. 4, p. 1, doi. 10.1002/hon.3289
    By:
    • Bellofiore, Claudia;
    • Benvenuti, Pietro;
    • Mina, Roberto;
    • Basset, Marco;
    • Foli, Andrea;
    • Nanci, Martina;
    • Nuvolone, Mario;
    • Guida, Gianluigi;
    • Attanasio, Andrea;
    • Mussinelli, Roberta;
    • Mangiacavalli, Silvia;
    • Cartia, Claudio Salvatore;
    • Masoni, Valeria;
    • Palumbo, Michele;
    • Cani, Lorenzo;
    • Oliva, Stefania;
    • Consoli, Ugo;
    • Conticello, Concetta;
    • Di Raimondo, Francesco;
    • Arcaini, Luca
    Publication type:
    Article
    33
    34
    35
    36
    37
    38
    39

    Combination of the PD‐1 inhibitor Nivolumab and Immunomodulatory Drug Lenalidomide in Relapsed Hodgkin and Large B‐cell Lymphoma: Results from a Phase I/II Study.

    Published in:
    Hematological Oncology, 2023, v. 41, p. 597, doi. 10.1002/hon.3164_447
    By:
    • Bond, D. A.;
    • Wei, L.;
    • Yildiz, V.;
    • Reneau, J.;
    • Sawalha, Y.;
    • Christian, B.;
    • Brammer, J.;
    • Epperla, N.;
    • Koff, J.;
    • Dendorfer, A.;
    • Yang, L.;
    • Baiocchi, R.;
    • Voorhees, T.;
    • Sigmund, A. M.;
    • Hanel, W.;
    • Shindiapina, P.;
    • Denlinger, N.;
    • Penza, S.;
    • Jaglowski, S.;
    • Bezerra, E.
    Publication type:
    Article
    40
    41
    42

    Venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed/refractory (R/R) and treatment‐naïve (TN) mantle cell lymphoma (MCL).

    Published in:
    Hematological Oncology, 2023, v. 41, p. 582, doi. 10.1002/hon.3164_437
    By:
    • Melani, C. J.;
    • Lakhotia, R.;
    • Pittaluga, S.;
    • Phelan, J. D.;
    • Yang, Y.;
    • Davies‐Hill, T.;
    • Simard, J.;
    • Muppidi, J.;
    • Huang, D. W.;
    • Thomas, C. J.;
    • Ceribelli, M.;
    • Tosto, F. A.;
    • Pradhan, A.;
    • Juanitez, A. M.;
    • Rimsza, L. M.;
    • Jacob, A.;
    • Simmons, H.;
    • Steinberg, S. M.;
    • Jaffe, E. S.;
    • Staudt, L. M.
    Publication type:
    Article
    43

    Phase 1 trial of EO2463 peptide‐based immunotherapy as monotherapy and in combination with lenalidomide and rituximab in indolent non‐Hodgkin lymphoma; EONHL1‐20/SIDNEY.

    Published in:
    Hematological Oncology, 2023, v. 41, p. 581, doi. 10.1002/hon.3164_435
    By:
    • Pinto, A. A.;
    • Bosch, F.;
    • Bisneto, J. C. Villasboas;
    • Sanz, R. García;
    • Garcia, C. Grande;
    • Smith, S. D.;
    • Wallace, D. S.;
    • Arcaini, L.;
    • Merryman, R.;
    • Marolleau, J.;
    • De Filippi, R.;
    • Chêne, L.;
    • Bonny, C.;
    • Fagerberg, J.;
    • Friedberg, J. W.;
    • Ansel, S.;
    • Armand, P.;
    • Zinzani, P. L.
    Publication type:
    Article
    44
    45
    46
    47
    48
    49
    50